Swedish Orphan Biovitrum AB

SOBI

SE0000872095

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:58 2024-05-06 am EDT			5-day change	1st Jan Change
282 ^SEK	+0.71%		-0.49%	+5.62%

Apr. 26	Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug	MT
Apr. 26	Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A	CI

Swedish Orphan Biovitrum AB Provides Financial Outlook for the Full Year 2021

October 11, 2021 at 01:30 pm EDT

Swedish Orphan Biovitrum AB (publ) provided financial outlook for the full year 2021. Revenue for the full-year 2021 is expected to be in the range of SEK 14,500 million - SEK 15,000 million (previously SEK 14,000 million-15,000 million).

Latest news about Swedish Orphan Biovitrum AB

Sobi Wins EU Regulatory Panel's Positive Opinion for Hemophilia A Drug	Apr. 26	MT
Sobi Receives Positive CHMP Opinion Recommending Approval of efanesoctocog alfa for Once-Weekly Treatment of Haemophilia A	Apr. 26	CI
Sobi's SEK10 Billion Note Program Gets Regulatory Nod in Sweden	Apr. 26	MT
Transcript : Swedish Orphan Biovitrum AB, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Swedish Orphan Biovitrum AB Provides Earnings Guidance for 2024	Apr. 25	CI
Certain Shares of Swedish Orphan Biovitrum AB are subject to a Lock-Up Agreement Ending on 14-MAR-2024.	Mar. 13	CI
Sobi to Expand in South Korea via Rare Disease JV with Handok	Feb. 13	MT
US Futures, European Stocks Mixed	Feb. 12	DJ
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	Feb. 12	MT
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	Feb. 12	CI
Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says	Feb. 09	MT
Transcript : Swedish Orphan Biovitrum AB, Q4 2023 Earnings Call, Feb 08, 2024	Feb. 08
Swedish Orphan Biovitrum AB Provides Revenue Guidance for the Year 2024	Feb. 08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 08	CI
Swedish Orphan Biovitrum AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Sobi's Profit to Get Royalty Boost as Sanofi Partnerships Outperform, RBC Says	Feb. 02	MT
Ericsson: new CFO in early April	Jan. 23	CF
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health...	Jan. 05
Swedish Orphan Chairman Steps Down, Successor Named	Jan. 05	MT
Swedish Orphan Biovitrum AB Announces Resignation of Bo Jesper Hansen as Chairman of the Board and Board Member	Jan. 05	CI
Nordic Shares Closed Up Thursday; Schibsted Series B Topped Leaders	Nov. 23	DJ
AstraZeneca prioritizes US for RSV drug amid surge in cases	Nov. 10	RE
Swedish Orphan Biovitrum Completes Issuance, Repurchase of Convertible Shares	Nov. 01	MT
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement	23-10-31	CI

Chart Swedish Orphan Biovitrum AB

Duration

Period

More charts

Company Profile

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Swedish Orphan Biovitrum AB

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

282 SEK

Average target price

317.8 SEK

Spread / Average Target

+12.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SWEDISH ORPHAN BIOVITRUM AB	+5.62%	8.81B
CSL LIMITED	-3.89%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-14.43%	31.67B
UCB	+51.20%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.85%	15.65B
INCYTE CORPORATION	-13.87%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-7.87%	11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-39.40%	11.61B
INNOVENT BIOLOGICS, INC.	-5.26%	8.5B

Biopharmaceuticals